Charlson M E
Surg Gynecol Obstet. 1985 May;160(5):393-9.
The prognostic impact of pretreatment delays was examined in an inception cohort of patients with carcinoma of the breast. Patients with delays of three months or more had a more advanced clinical stage than those with shorter delays; however, within each stage, prognosis was not affected by delay. Patients with delays of three months or more had a worse over-all prognosis than those with short delays because they had a less favorable distribution by anatomic stage and they had more adverse changes in clinical state. Nonetheless, progression of disease did not invariably occur among patients with longer delays. Patients with long delays, but without adverse changes had an excellent prognosis. The data suggests that carcinoma of the breast does not always progress as a function of time. Estimates were made of the number of patients who would benefit by reducing pretreatment delay. In this cohort, a maximum of 5 per cent of the patients were adversely affected by longer delays. Reducing delay may benefit only a small proportion of women with carcinoma of the breast.
在一组乳腺癌初诊患者中研究了治疗前延迟的预后影响。延迟三个月或更长时间的患者比延迟时间较短的患者临床分期更晚；然而，在每个分期内，预后不受延迟的影响。延迟三个月或更长时间的患者总体预后比延迟时间短的患者更差，因为他们按解剖分期的分布更不理想，且临床状态有更多不良变化。尽管如此，延迟时间较长的患者疾病并非总是进展。延迟时间长但无不良变化的患者预后良好。数据表明，乳腺癌并不总是随时间推移而进展。对通过减少治疗前延迟而受益的患者数量进行了估计。在这组患者中，最多5%的患者受到较长延迟的不利影响。减少延迟可能仅使一小部分乳腺癌女性受益。
